Overview

NCI Definition [1]:
An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon administration, CSF1R inhibitor ABSK021 targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.

Absk021 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating absk021, 1 is phase 1 (1 open).

Malignant solid tumor is the most common disease being investigated in absk021 clinical trials [2].

Drug Details

Synonyms [2]:
absk-021, csf-1r inhibitor absk021, absk 021|
Drug Target(s) [2]:
CSF1R
NCIT ID [1]:
C173651

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.